All results

2 results for single arm open label multicenter study evaluating long term safety tolerability and

• First-In-Human Study of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221

  This study is an international, multi-center, study of Pompe disease patients that are currently receiving enzyme-replacement therapy (ERT). The purpose of…

  Ages

  18 Years - 75 Years

  Sexes

  All

• u-STOP LVAD Bleed

  This is a Phase I, single ascending dose, first in human, open-label, non-controlled, dose-escalation trial that will investigate intravenous infusions of…

  Ages

  18 Years - 80 Years

  Sexes

  All